Roivant and Arbutus have a month to decide if they're going to set up a new company for RNA delivery.
A Celgene spinout known as Celularity with some of the biggest names in biotech and Silicon Valley has raised $250 million for its work in cancer.
The careful optimization of tumor-bearing humanized models leads to highly useful preclinical immuno-oncology platforms for accelerated immunotherapy…
Vertex Pharma now has a pair of studies backing up its new drug VX-150, suggesting it can provide opioidlike pain relief without the addiction risks.
The biotech is adding 510 patients to the phase 3 aducanumab trials after seeing more “variability” than expected in a sample size re-estimation.
Bristol-Myers is committing $3.6 billion to a deal that gives Nektar most of the profits and freedom to develop the drug in other combinations.
The setback comes 12 months after Merck pulled the plug on a trial in patients with more advanced forms of the disease.
The Bill & Melinda Gates Foundation has teamed up with big pharma Novartis and its experimental drug for certain diarrheal diseases.
Tetraphase's lead candidate, eravacycline, failed to best Merck’s ertapenem in complicated UTIs.
After disappointing data in leukemia, France’s Erytech is refocusing its red blood cell-encapsulated drug therapy to solid tumors.
The ROCK2 inhibitor had a stronger effect on FVC than standard of care, but the lack of detail in the top-line data leave scope for doubts.